Abivax (ABVX) Total Non-Current Liabilities (2021 - 2026)
Abivax (ABVX) posted quarterly Total Non-Current Liabilities of $64.8 million for Q1 2026, down 9.18% year-over-year from $71.3 million in Q1 2025, and down 15.85% quarter-over-quarter from $77.0 million in Q4 2025.
Abivax (ABVX) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Abivax's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $64.8 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 9.18% year-over-year to $64.8 million; the TTM figure through Mar 2026 stood at $64.8 million (down 9.18% YoY), while the FY2025 annual figure was $77.0 million, up 1.95% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $64.8 million, down from $77.0 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $84.1 million in Q2 2024, with the low at $17.2 million in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $71.3 million (2025), against an average of $63.2 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities tumbled 70.48% in 2022, then jumped 151.96% in 2023.
- Abivax's Total Non-Current Liabilities stood at $17.2 million in 2022, then surged by 151.96% to $43.4 million in 2023, then surged by 73.86% to $75.5 million in 2024, then grew by 1.95% to $77.0 million in 2025, then decreased by 15.85% to $64.8 million in 2026.
- Business Quant data shows ABVX's Total Non-Current Liabilities at $64.8 million in Q1 2026, $77.0 million in Q4 2025, and $72.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 64.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.76 Mn |
| Dec 31, 2025 | 76.96 Mn |
| Sep 30, 2025 | 72.54 Mn |
| Jun 30, 2025 | 62.90 Mn |
| Mar 31, 2025 | 71.31 Mn |
| Dec 31, 2024 | 75.49 Mn |
| Jun 30, 2024 | 84.06 Mn |
| Dec 31, 2023 | 43.42 Mn |
| Dec 31, 2022 | 17.23 Mn |
| Dec 31, 2021 | 58.38 Mn |